Zoetis (ZTS) Q3 2025: Livestock Grows 10% as Companion Animal Volume Stalls
Zoetis’ livestock segment delivered double-digit growth, offsetting flat companion animal volumes as U.S. therapeutic visits declined and competitive pressure intensified in dermatology and pain franchises. Management narrowed full-year guidance, citing macro softness and aggressive promotions, but flagged early signs of stabilization in challenged areas. All eyes now turn to pipeline execution and the potential for a volume recovery in 2026 as the business leans on innovation and diversification.
Summary
- Livestock Resilience: Double-digit livestock growth outpaced companion animal, anchoring overall results.
- Therapeutic Visit Declines: U.S. companion animal volumes stagnated as clinic visits dropped for key categories.
- Pipeline Execution Watch: Next-generation OA pain launches and international expansion are critical for 2026 growth.
Performance Analysis
Zoetis posted 4% organic operational revenue growth in Q3, with livestock revenue up 10% and companion animal revenue up just 2%. The livestock segment, now in its third year of above-market growth, contributed $725 million and offset stagnation in the core companion animal business. U.S. revenue was flat for companion animal, while international growth was more robust, especially in parasiticides.
Volume growth was zero for the quarter, with all gains driven by pricing, which trended near the upper end of Zoetis’ typical 2–4% range. The OA pain franchise fell 11% globally, with Librella facing social media-driven misperceptions and reduced new patient starts. Dermatology grew 3% globally, but U.S. results were muted by competitive launches and clinic softness. Parasiticides, led by Semperica Trio, maintained share but growth moderated sharply against a strong prior-year comp. Distributor inventory levels remained at historical lows, suggesting no artificial volume boost.
- Livestock Growth Engine: Broad-based demand and vaccine-led poultry strength drove livestock to a 10% increase, providing portfolio diversification.
- Companion Animal Headwinds: Flat U.S. performance and OA pain declines highlight volume sensitivity to therapeutic visit trends and competitive intensity.
- Price-Driven Topline: All organic growth was price-driven, raising questions about sustainable volume recovery as competitive discounting rises.
Margin discipline persisted as adjusted gross margin rose 90 basis points, aided by product mix and cost controls. Adjusted net income grew 9% organically, reflecting resilience amid mixed end-market conditions.
Executive Commentary
"Our resilient growth engine remains strong, fueled by our market-leading innovation and pipeline, a diversified portfolio across species and geographies, global reach, and trusted brands that continue to lead their categories and remain essential to veterinarians, despite some near-term headwinds."
Kristen Peck, Chief Executive Officer
"We are operating from a position of strength, supported by the broadest portfolio in the industry, even while we are navigating some temporary headwinds. We remain confident in the long-term growth potential of both our business and the broader animal health market."
Whitney Joseph, Chief Financial Officer
Strategic Positioning
1. Livestock as Portfolio Anchor
Livestock, animal protein therapeutics and vaccines, delivered its third consecutive year of above-market growth, demonstrating resilience against companion animal volatility. The business benefited from rising protein consumption and successful vaccine innovation, with poultry and fish both cited as growth drivers. This segment now serves as a core ballast for Zoetis, helping to offset cyclical or competitive pressures in companion animal.
2. Companion Animal: Volume Sensitivity and Competitive Dynamics
Companion animal, pet therapeutics and diagnostics, faced headwinds as U.S. therapeutic visits declined, impacting new patient starts in dermatology and OA pain. Competitive launches in dermatology and aggressive discounting pressured share, though management emphasized that share losses were modest and launch-related promotions tend to be short-lived. The business remains highly price-sensitive, with all growth in Q3 coming from price rather than volume.
3. Innovation-Driven Pipeline and Lifecycle Management
Zoetis’ innovation pipeline, new product development and lifecycle extensions, remains a strategic priority. The company highlighted upcoming launches for Lanivia and Portela, both next-generation OA pain monoclonal antibodies, with first approvals in Canada and Europe. Management is focused on applying learnings from the Librella launch—especially around education and specialist engagement—to drive a more successful uptake for new products. Over 130 geographic expansions and product lifecycle innovations were executed year-to-date, reinforcing Zoetis’ commitment to pipeline-led growth.
4. Commercial Model Evolution
The U.S. commercial structure is being overhauled to create a leaner, more agile field organization. Single point of contact coverage and alternative channels (retail and home delivery) are being emphasized to drive compliance and convenience for pet owners, aiming to offset clinic traffic softness and meet evolving customer expectations.
5. Cost Discipline and Margin Management
Cost discipline, expense control and margin optimization, remains in focus. Adjusted operating expenses grew just 1% operationally, and gross margin benefited from product mix, price, and the divestiture of lower-margin businesses. Margin expansion supports bottom-line stability even as topline growth moderates.
Key Considerations
Zoetis’ Q3 results underscore the importance of portfolio diversification, pipeline execution, and commercial agility as the animal health market navigates macro and competitive headwinds.
Key Considerations:
- Livestock Offsets Companion Weakness: Robust livestock performance provides a crucial buffer as companion animal volumes stall.
- Therapeutic Visit Trends Matter: Sustained declines in U.S. therapeutic visits for dermatology and OA pain are pressuring volume and new patient starts.
- Competitive Intensity Rising: Dermatology and OA pain franchises face aggressive launch promotions, with management expecting these impacts to be temporary but material for near-term results.
- Pipeline Launches Under Scrutiny: The success of Lanivia and Portela launches in 2026 will be pivotal for restoring growth in OA pain and expanding into underpenetrated markets.
- Commercial Model Adaptation: Shifts toward alternative channels and field force restructuring are designed to meet changing customer needs and drive compliance, but execution risk remains.
Risks
Volume growth is highly sensitive to U.S. therapeutic visit trends, with further declines potentially prolonging stagnation in core franchises. Competitive pressure in dermatology and OA pain is intensifying, with aggressive discounting and new launches threatening share and pricing. Social media-driven misperceptions around Librella and other products could impede adoption and require sustained education efforts. Macro uncertainty and distributor inventory dynamics add further unpredictability to quarterly results.
Forward Outlook
For Q4 2025, Zoetis guided to:
- Organic operational revenue growth in the 5.5% to 6.5% range for the full year
- Adjusted net income growth of 5.5% to 7% for the full year
EPS guidance was maintained at $5.90 to $6.00 (reported) and $6.30 to $6.40 (adjusted). Management expects macro softness, competitive launches, and subdued clinic traffic to persist in Q4, but flagged early signs of stabilization in OA pain and a robust launch pipeline for 2026.
- Livestock is expected to continue outperforming, providing portfolio stability
- Volume recovery in companion animal will depend on improvement in therapeutic visits and successful new product launches
Takeaways
Zoetis’ diversified model is cushioning macro and competitive shocks, but volume recovery in companion animal is now the central challenge.
- Livestock Diversification: Strong livestock growth is providing ballast and reducing reliance on U.S. pet market cycles.
- Execution Watch: The upcoming launches of Lanivia and Portela, and the effectiveness of commercial restructuring, will determine if Zoetis can restore high-single-digit growth in 2026.
- Future Focus: Investors should monitor U.S. therapeutic visit trends, competitive intensity in dermatology, and early adoption of next-generation OA pain products for signals of a volume inflection point.
Conclusion
Zoetis’ Q3 showed the value of portfolio breadth as livestock growth offset companion animal headwinds. With all organic growth coming from price, volume recovery and new product execution are now critical. The company’s innovation pipeline and commercial agility will be tested in the coming quarters as it seeks to reignite growth in challenged franchises and defend its leadership in animal health.
Industry Read-Through
Zoetis’ results highlight a broader animal health industry trend: Livestock therapeutics and vaccines are increasingly important as pet therapeutics face volume and competitive pressure. Clinic visit trends and alternative channel adoption (retail and home delivery) are now central watchpoints for all players. Pipeline execution and lifecycle management are becoming more critical as established franchises mature and face new entrants. Competitors will need to balance innovation, pricing, and commercial model adaptation to sustain growth in a market where volume is no longer a given.